Shows promise in preventing monoA new study suggests that a vaccine against the Epstein-Barr virus can infectious mononucleosis, prevent commonly as mono or known the study glandular fever here . will be in the December 15 issue of The Journal of Infectious Diseases, now published online.

Founded in 1805, the Royal Society of Medicine is an independent the exchange of knowledge the exchange of knowledge, information and ideas in medical science and continued improvement of human health.

On Pneumovax 23Pneumovax II 23, the only pneumococcal vaccine in the USA has authorized for use in adults. According the SPC for Pneumovax II is 23, of the vaccine of routine vaccination of men 50 years of age or over is recommended and then select other people aged 2 years and over with certain risk factors. In particular Pneumovax II is advised 23 represents immunocompetent individuals aged between 2 to with chronic cardiovascular disease , of chronic pulmonary disease , diabetes mellitus, the or with AlcoholismAlzheimer, chronic liver disease cerebrospinal fluid leaks and functional or anatomical asplenia . Middle of the upper 23 recommended even by prescribing Details of those aged 2 years and over who are living in special environments or social settings . Determined immunocompromised people at 2 and older are recommend even for Pneumovax associated with with an HIV infection, leukemia, lymphoma, Hodgkins disease, multiple myeloma generalized malignancy, chronic renal failure or nephrotic syndrome; those receiving immunosuppressive chemo have received and those of , organ or bone marrow transplant. Vaccination with Pneumovax 23rd not no 100 % protection from pneumococcal infectious. Pneumovax II is 23 as a single dose subcutaneously or .

Other articles from category "gastroenterology":

Random articles